PMID: 40040742 Soliman Y, Yakandawala U, Leong C, et al
This is fundamentally different from how semaglutide or tirzepatide work
Primary Analysis CagriSema 2.4mg: 23.0% mean weight loss Zepbound 15mg: 25.5% mean weight loss Treatment Regimen Estimand (Real-World Effectiveness) CagriSema: 20.2% weight loss Zepbound: 23.6% weight loss Because CagriSema did not demonstrate non-inferiority, the trials primary endpoint was not met
However, the quality of evidence is low due to the limited number of randomized controlled studies, small sample sizes and the limited studies in adults (87)
Krajnc N, Itariu B, Macher S, Marik W, Harreiter J, Michl M, et al
The agreement will expand access to the drug to regions of India where Lilly does not have an existing footprint